Ignite Creation Date:
2024-05-05 @ 9:22 PM
Last Modification Date:
2024-10-26 @ 10:02 AM
Study NCT ID:
NCT00863811
Status:
WITHDRAWN
Last Update Posted:
2012-06-06
First Post:
2009-03-17
Brief Title:
Effects of Forskolin on Intraocular Pressure in Glaucomatous Patients Under Treatment With Either Beta-blockers or Prostaglandins Eye Drops
Sponsor:
Sooft Italia
Organization:
Sooft Italia
Study Overview
Official Title:
Effects of the Oral Administration of an Association of Forskolin With Rutin and Vitamins B on Intraocular Pressure in Patients Affected by Primary Open Angle Glaucoma and Treated With Either Beta-blockers or Prostaglandin Eye Drops
Status:
WITHDRAWN
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
loss of interest before enrolment started
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Elevated intraocular pressure is still the main risk factor for development and progression of glaucoma Several drugs exist on the market that may decrease IOP in glaucomatous patients However some patients cannot reach the target pressure despite a multitherapy with a combination of drugs and are therefore addressed to surgical treatments Forskolin is a natural compound that is a receptor-independent adenyl-cyclase activator that increases intracellular cAMP It has been shown to be able to decrease IOP after topical application by a mechanism that is not used by the other drugs Aim of the present study is to see whether oral administration of a food supplement containing forskolin KRONEK has any effect on the IOP of POAG patients with stable IOP obtained by treatment with either beta-blockers or prostaglandins
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None